Forward-Looking Statements
This report contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts,
included in this press release regarding Ascendis future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis
ability to achieve blockbuster status for multiple products and expand its engine for future innovation, (ii) Ascendis ability to achieve its 2024 corporate milestones and Vision 2030, (iii) Ascendis ability to fulfill Vision 3x3,
(iv) Ascendis plan to submit a supplemental Biologics License Application to FDA for TransCon hGH in the second quarter of 2024, (v) the timing of topline results from the Phase 2 trial in Turner syndrome, (vi) Ascendis
expectations with respect to SKYTROFA revenue for 2023 and 2024, (vii) Ascendis plan to launch TransCon PTH in Germany in January 2024, (viii) TransCon PTHs PDUFA date of May 14, 2024, (ix) Ascendis plans to launch TransCon
PTH in the U.S. in the third quarter of 2024, if approved, (x) the timing of topline results from the ApproaCH Trial, (xi) Ascendis plan to submit a New Drug Application for TransCon CNP for children with achondroplasia,
(xii) Ascendis plan to submit an Investigational New Drug application or similar for TransCon CNP in adults with achondroplasia; (xiii) the timing of topline annualized height velocity data from the COACH Trial,
(xiv) Ascendis ability to expand its global reach through exclusive sales & distribution agreements with geographic market leaders, (xv) Ascendis expectations with regard to the completion of enrollment in BelieveIT-201, (xvi) Ascendis plan to provide a clinical update from the Phase 2 portion of indication-specific, dose expansion cohorts in the IL-Believe Trial,
(xvii) Ascendis expectations regarding its financial results and performance in 2023 and 2024, (xviii) Ascendis Vision 2030 (xix) Ascendis ability to apply its TransCon technology platform to build a leading, fully
integrated biopharma company, and (xx) Ascendis use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not
actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could
differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that
Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis products and product candidates; unforeseen safety or efficacy results in Ascendis development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis development programs; unforeseen selling, general and
administrative expenses, other research and development expenses and Ascendis business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen
delays; Ascendis ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including inflation, the effects on its
business from the worldwide COVID-19 pandemic and ongoing conflicts such as that in the region surrounding Ukraine and Russia. For a further description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis business in general, see Ascendis Annual Report on Form 20-F filed with the U.S.
Securities and Exchange Commission (SEC) on February 16, 2023 and Ascendis other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations,
acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.